In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually disease progression or maybe the members are not able to tolerate the study drugs. Probable new methods for that analysis and treatment of AML. (A) https://abbv-744inclinicaltrialsf81256.ja-blog.com/32114500/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained